Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To compare evidence of preservation of joint structure after administration of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone in MTX-naïve patients with active RA, as measured by changes from baseline using a standardized, validated method, such as the van der Heijde modified Sharp score at Month 6. 2. To compare the efficacy of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone for the treatment of signs and symptoms of rheumatoid arthritis (RA) in MTX-naïve patients with active RA, as measured by ACR70 response rates at Month 6. 3. To evaluate the safety and tolerability of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone in MTX-naïve patients with active RA for 24 months.
Critère d'inclusion
- Moderate to severe active rheumatoid arthritis